| US 7,531,516 B2 | ||
| Peptidic compounds selectively binding to P-selectin | ||
| Thomas Jacobus Maria Molenaar, Leiden (Netherlands); Johan Kuiper, Gouda (Netherlands); Theodorus Josephus Cornelis Van Berkel, Haarlem (Netherlands); and Erik Anna Biessen, Leiden (Netherlands) | ||
| Assigned to Astellas Pharma Europe B.V., Leiderdorp (Netherlands) | ||
| Appl. No. 10/488,509 PCT Filed Aug. 28, 2002, PCT No. PCT/NL02/00566 § 371(c)(1), (2), (4) Date Mar. 02, 2004, PCT Pub. No. WO03/020753, PCT Pub. Date Mar. 13, 2003. |
||
| Claims priority of application No. 01203314 (EP), filed on Sep. 03, 2001. | ||
| Prior Publication US 2005/0004035 A1, Jan. 06, 2005 | ||
| Int. Cl. A61K 38/00 (2006.01); A61K 38/08 (2006.01); A61K 38/10 (2006.01); A61K 38/16 (2006.01); C07K 7/00 (2006.01); C07K 7/06 (2006.01); C07K 7/08 (2006.01); C07K 14/00 (2006.01) | ||
| U.S. Cl. 514—16 [530/300; 530/326; 530/327; 530/328; 530/329; 514/2; 514/13; 514/14; 514/15] | 22 Claims |
| 1. A peptide compound with affinity to human P-selectin of the sequence XAXA3A1A2A1Z, or a pharmaceutically acceptable acid or base addition salt thereof, wherein:
each A1 is independently a D- or L-cysteine (C), D- or L-methionine (M), or D- or L-valine (V);
A2 is a D- or L-aspartic acid (D);
A3 is a D- or L-phenylalanine (F) or D- or L-tryptophan (W);
AX is a D- or L- glutamic acid (E), D- or L-aspartic acid (D), D- or L-cysteine (C) or D- or L-glycine (G);
X marks the N-terminal side of said sequence and is a hydrogen or contains 1 to 6 D- or L-amino acid residues; and Z marks
the C-terminal side of said sequence and is a hydroxyl or contains 1 to 11 D- or L-amino acid residues terminated by a hydroxyl,
wherein X and Z together can form a cyclic system, provided that when the compound is cyclized by a Cys-Cys disulfide bond,
each participating Cys residue is a member of X and Z respectively.
|